These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 17252287)
1. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Phan LK; Hoff PM Dis Colon Rectum; 2007 Mar; 50(3):395-8. PubMed ID: 17252287 [TBL] [Abstract][Full Text] [Related]
2. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. De Dosso S; Martin V; Zanellato E; Frattini M; Saletti P Tumori; 2010; 96(4):627-8. PubMed ID: 20968146 [TBL] [Abstract][Full Text] [Related]
3. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Kim DW; Byer J; Kothari N; Mahipal A; Chang YD; Kim RD Oncology; 2017; 92(4):190-196. PubMed ID: 28152526 [TBL] [Abstract][Full Text] [Related]
4. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313 [TBL] [Abstract][Full Text] [Related]
5. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. Khawandanah M; Baxley A; Pant S J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343 [TBL] [Abstract][Full Text] [Related]
6. Cetuximab in refractory squamous cell carcinoma of the anal canal. Rogers JE; Eng C J Gastrointest Cancer; 2014 Dec; 45 Suppl 1():198-200. PubMed ID: 24908401 [No Abstract] [Full Text] [Related]
7. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma. Valery M; Cervantes B; Smolenschi C; Boilève A; Boige V; Malka D; Hollebecque A; Ducreux M Dig Liver Dis; 2023 Mar; 55(3):407-411. PubMed ID: 36088220 [TBL] [Abstract][Full Text] [Related]
8. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Personeni N; Hendlisz A; Gallez J; Galdon MG; Larsimont D; Van Laethem JL; Nagy N; Barette M; Paesmans M; Cardoso F; Bleiberg H Semin Oncol; 2005 Dec; 32(6 Suppl 9):S59-62. PubMed ID: 16399434 [TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976 [TBL] [Abstract][Full Text] [Related]
10. Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer. Hebbar M; Di Fioré F; Conroy T; Giraud C; Gasnault L; Fournier C; Péreira R; Bouché O; Fournier P; Deligny N; Joly JP; Maes P; Rad E; Michel P; Adenis A Oncology; 2007; 73(3-4):185-91. PubMed ID: 18418011 [TBL] [Abstract][Full Text] [Related]
11. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Kim S; Prichard CN; Younes MN; Yazici YD; Jasser SA; Bekele BN; Myers JN Clin Cancer Res; 2006 Jan; 12(2):600-7. PubMed ID: 16428506 [TBL] [Abstract][Full Text] [Related]
13. Cetuximab plus irinotecan in refractory colorectal cancer patients. Gil Delgado M; Spano JP; Khayat D Expert Rev Anticancer Ther; 2007 Apr; 7(4):407-13. PubMed ID: 17428161 [TBL] [Abstract][Full Text] [Related]
14. Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab. Lerner J; Michel M; Dasanu CA J Oncol Pharm Pract; 2020 Jun; 26(4):1025-1028. PubMed ID: 31684821 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013 [TBL] [Abstract][Full Text] [Related]
16. Integration of novel agents in the treatment of colorectal cancer. Iqbal S; Lenz HJ Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512 [TBL] [Abstract][Full Text] [Related]
17. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971 [TBL] [Abstract][Full Text] [Related]
18. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Mahtani RL; Macdonald JS Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011 [TBL] [Abstract][Full Text] [Related]